Cargando…
Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
Sintilimab is an anti-programmed cell death receptor-1 antibody. The phase III clinical trial ORIENT-12 confirmed the safety of sintilimab combined with pemetrexed/platinum in the treatment of advanced squamous non-small cell lung cancer. Skin reactions are the most commonly reported adverse events...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Dermatological Association; The Korean Society for Investigative Dermatology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608386/ https://www.ncbi.nlm.nih.gov/pubmed/37853877 http://dx.doi.org/10.5021/ad.21.072 |